Advertisement

Venous Thromboembolism in the Inflammatory Rheumatic Diseases

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Rheumatic Disease Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Galloway J.
        • Barrett K.
        • Irving P.
        • et al.
        Risk of venous thromboembolism in immune-mediated inflammatory diseases: a UK matched cohort study.
        RMD Open. 2020; 6: e001392
        • Ruiz-Sada P.
        • Mazzolai L.
        • Braester A.
        • et al.
        Venous thromboembolism in patients with autoimmune disorders: a comparison between bleeding complications during anticoagulation and recurrences after its discontinuation.
        Br J Haematol. 2022; 197: 489-496
        • Yusuf H.R.
        • Hooper W.C.
        • Beckman M.G.
        • et al.
        Risk of venous thromboembolism among hospitalizations of adults with selected autoimmune diseases.
        J Thromb Thrombolysis. 2014; 38: 306-313
        • Kragstrup T.W.
        • Glintborg B.
        • Svensson A.L.
        • et al.
        Waiting for JAK inhibitor safety data.
        RMD Open. 2022; 8: e002236
        • Hu L.J.
        • Ji B.
        • Fan H.X.
        Venous thromboembolism risk in rheumatoid arthritis patients: a systematic review and updated meta-analysis.
        Eur Rev Med Pharmacol Sci. 2021; 25: 7005-7013
        • Li L.
        • Lu N.
        • Avina-Galindo A.M.
        • et al.
        The risk and trend of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a general population-based study.
        Rheumatology (Oxford). 2021; 60: 188-195
        • Molander V.
        • Bower H.
        • Frisell T.
        • et al.
        Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden.
        Ann Rheum Dis. 2021; 80: 169-175
        • Ozen G.
        • Pedro S.
        • Schumacher R.
        • et al.
        Risk factors for venous thromboembolism and atherosclerotic cardiovascular disease: do they differ in patients with rheumatoid arthritis?.
        RMD Open. 2021; 7: e001618
        • Federico L.E.
        • Johnson T.M.
        • England B.R.
        • et al.
        Circulating Adipokines and Associations with Incident Cardiovascular Disease in Rheumatoid Arthritis.
        Arthritis Care Res (Hoboken). 2022; (In press)https://doi.org/10.1002/acr.24885
        • Ungprasert P.
        • Srivali N.
        • Kittanamongkolchai W.
        Ankylosing spondylitis and risk of venous thromboembolism: A systematic review and meta-analysis.
        Lung India. 2016; 33: 642-645
        • Bengtsson K.
        • Forsblad-d'Elia H.
        • Lie E.
        • et al.
        Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study.
        Arthritis Res Ther. 2017; 19: 102
        • Eriksson J.K.
        • Jacobsson L.
        • Bengtsson K.
        • et al.
        Is ankylosing spondylitis a risk factor for cardiovascular disease, and how do these risks compare with those in rheumatoid arthritis?.
        Ann Rheum Dis. 2017; 76: 364-370
        • Aviña-Zubieta J.A.
        • Chan J.
        • De Vera M.
        • et al.
        Risk of venous thromboembolism in ankylosing spondylitis: a general population-based study.
        Ann Rheum Dis. 2019; 78: 480-485
        • Ogdie A.
        • Kay McGill N.
        • Shin D.B.
        • et al.
        Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study.
        Eur Heart J. 2018; 39: 3608-3614
        • Gazitt T.
        • Pesachov J.
        • Lavi I.
        • et al.
        The association between psoriatic arthritis and venous thromboembolism: a population-based cohort study.
        Arthritis Res Ther. 2022; 24: 16
        • Damian A.C.
        • Colaco K.
        • Rohekar S.
        • et al.
        The incidence and risk factors for venous thromboembolic events in patients with psoriasis and psoriatic arthritis.
        Semin Arthritis Rheum. 2021; 51: 547-552
        • Goulielmos G.N.
        • Zervou M.I.
        Risk of Venous Thromboembolism in Ankylosing Spondylitis and Rheumatoid Arthritis: Genetic Aspects.
        J Rheumatol. 2021; 48: 1492-1493
        • Yafasova A.
        • Fosbøl E.L.
        • Schou M.
        • et al.
        Long-Term Cardiovascular Outcomes in Systemic Lupus Erythematosus.
        J Am Coll Cardiol. 2021; 77: 1717-1727
        • Aviña-Zubieta J.A.
        • Vostretsova K.
        • De Vera M.A.
        • et al.
        The risk of pulmonary embolism and deep venous thrombosis in systemic lupus erythematosus: A general population-based study.
        Semin Arthritis Rheum. 2015; 45: 195-201
        • Mok C.C.
        • Ho L.Y.
        • Yu K.L.
        • et al.
        Venous thromboembolism in southern Chinese patients with systemic lupus erythematosus.
        Clin Rheumatol. 2010; 29: 599-604
        • Mok C.C.
        • Tang S.S.
        • To C.H.
        • et al.
        Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups.
        Arthritis Rheum. 2005; 52: 2774-2782
        • Ahlehoff O.
        • Wu J.J.
        • Raunsø J.
        • et al.
        Cutaneous lupus erythematosus and the risk of deep venous thrombosis and pulmonary embolism: A Danish nationwide cohort study.
        Lupus. 2017; 26: 1435-1439
        • Chang J.C.
        • Mandell D.S.
        • Knight A.M.
        High Health Care Utilization Preceding Diagnosis of Systemic Lupus Erythematosus in Youth.
        Arthritis Care Res (Hoboken). 2018; 70: 1303-1311
        • Jakez-Ocampo J.
        • Rodriguez-Armida M.
        • Fragoso-Loyo H.
        • et al.
        Clinical characteristics of systemic lupus erythematosus patients in long-term remission without treatment.
        Clin Rheumatol. 2020; 39: 3365-3371
        • Kishore S.
        • Jatwani S.
        • Malhotra B.
        • et al.
        Systemic Lupus Erythematosus Is Associated With a High Risk of Venous Thromboembolism in Hospitalized Patients Leading to Poor Outcomes and a Higher Cost: Results From Nationwide Inpatient Sample Database 2003-2011.
        ACR Open Rheumatol. 2019; 1: 194-200
        • Gkrouzman E.
        • Peng M.
        • Davis-Porada J.
        • et al.
        Venous Thromboembolic Events in African American Lupus Patients in Association With Antiphospholipid Antibodies Compared to White Patients.
        Arthritis Care Res (Hoboken). 2022; 74: 656-664
        • Cooley I.
        • Derebail V.K.
        • Gibson K.L.
        • et al.
        Association of Lupus Nephritis Histopathologic Classification With Venous Thromboembolism-Modification by Age at Biopsy.
        Kidney Int Rep. 2021; 6: 1653-1660
        • Cervera R.
        • Khamashta M.A.
        • Font J.
        • et al.
        Morbidity and Mortality in Systemic Lupus Erythematosus During a 10-Year Period: A Comparison of Early and Late Manifestations in a Cohort of 1,000 Patients.
        Medicine. 2003; 82: 299-308
        • Akdogan A.
        • Kilic L.
        • Dogan I.
        • et al.
        Pulmonary hypertension in systemic lupus erythematosus: pulmonary thromboembolism is the leading cause.
        J Clin Rheumatol. 2013; 19: 421-425
        • Brouwer J.L.
        • Bijl M.
        • Veeger N.J.
        • et al.
        The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus.
        Blood. 2004; 104: 143-148
        • Sallai K.K.
        • Nagy E.
        • Bodó I.
        • et al.
        Thrombosis risk in systemic lupus erythematosus: the role of thrombophilic risk factors.
        Scand J Rheumatol. 2007; 36: 198-205
        • Elbagir S.
        • Grosso G.
        • Mohammed N.A.
        • et al.
        Associations with thrombosis are stronger for antiphosphatidylserine/prothrombin antibodies than for the Sydney criteria antiphospholipid antibody tests in SLE.
        Lupus. 2021; 30: 1289-1299
        • Nojima J.
        • Kuratsune H.
        • Suehisa E.
        • et al.
        Acquired activated protein C resistance associated with IgG antibodies against beta2-glycoprotein I and prothrombin as a strong risk factor for venous thromboembolism.
        Clin Chem. 2005; 51: 545-552
        • Ramirez G.A.
        • Mackie I.
        • Nallamilli S.
        • et al.
        Anti-protein C antibodies and acquired protein C resistance in SLE: novel markers for thromboembolic events and disease activity?.
        Rheumatology (Oxford). 2021; 60: 1376-1386
        • Svenungsson E.
        • Gustafsson J.T.
        • Grosso G.
        • et al.
        Complement deposition, C4d, on platelets is associated with vascular events in systemic lupus erythematosus.
        Rheumatology (Oxford). 2020; 59: 3264-3274
        • Peretz A.S.R.
        • Rasmussen N.S.
        • Jacobsen S.
        • et al.
        Galectin-3-binding protein is a novel predictor of venous thromboembolism in systemic lupus erythematosus.
        Clin Exp Rheumatol. 2021; 39: 1360-1368
        • Miranda S.
        • Park J.
        • Le Gal G.
        • et al.
        Prevalence of confirmed antiphospholipid syndrome in 18-50 years unselected patients with first unprovoked venous thromboembolism.
        J Thromb Haemost. 2020; 18: 926-930
        • Knight J.S.
        • Kanthi Y.
        Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome.
        Semin Immunopathol. 2022; 44: 347-362
        • Zuily S.
        • Clerc-Urmès I.
        • Bauman C.
        • et al.
        Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry.
        Lupus. 2020; (In press)https://doi.org/10.1177/0961203320940776
        • Bucci T.
        • Ames P.R.J.
        • Triggiani M.
        • et al.
        Cardiac and vascular features of arterial and venous primary antiphospholipid syndrome. The multicenter ATHERO-APS study.
        Thromb Res. 2022; 209: 69-74
        • Rosen K.
        • Raanani E.
        • Kogan A.
        • et al.
        Chronic thromboembolic pulmonary hypertension in patients with antiphospholipid syndrome: Risk factors and management.
        J Heart Lung Transpl. 2022; 41: 208-216
        • Foltyn Zadura A.
        • Memon A.A.
        • Stojanovich L.
        • et al.
        Factor H Autoantibodies in Patients with Antiphospholipid Syndrome and Thrombosis.
        J Rheumatol. 2015; 42: 1786-1793
        • Stachowicz A.
        • Zabczyk M.
        • Natorska J.
        • et al.
        Differences in plasma fibrin clot composition in patients with thrombotic antiphospholipid syndrome compared with venous thromboembolism.
        Sci Rep. 2018; 8: 17301
        • Celinska-Löwenhoff M.
        • Zabczyk M.
        • Iwaniec T.
        • et al.
        Reduced plasma fibrin clot permeability is associated with recurrent thromboembolic events in patients with antiphospholipid syndrome.
        Rheumatology (Oxford). 2018; 57: 1340-1349
        • Berti A.
        • Matteson E.L.
        • Crowson C.S.
        • et al.
        Risk of Cardiovascular Disease and Venous Thromboembolism Among Patients With Incident ANCA-Associated Vasculitis: A 20-Year Population-Based Cohort Study.
        Mayo Clin Proc. 2018; 93: 597-606
        • Hansrivijit P.
        • Trongtorsak A.
        • Gadhiya K.P.
        • et al.
        Incidence and risk factors of venous thromboembolism in ANCA-associated vasculitis: a metaanalysis and metaregression.
        Clin Rheumatol. 2021; 40: 2843-2853
        • Misra D.P.
        • Thomas K.N.
        • Gasparyan A.Y.
        • et al.
        Mechanisms of thrombosis in ANCA-associated vasculitis.
        Clin Rheumatol. 2021; 40: 4807-4815
        • Tracy A.
        • Subramanian A.
        • Adderley N.J.
        • et al.
        Cardiovascular, thromboembolic and renal outcomes in IgA vasculitis (Henoch-Schönlein purpura): a retrospective cohort study using routinely collected primary care data.
        Ann Rheum Dis. 2019; 78: 261-269
        • Ungprasert P.
        • Koster M.J.
        • Cheungpasitporn W.
        • et al.
        Inpatient burden and association with comorbidities of polyarteritis nodosa: National Inpatient Sample 2014.
        Semin Arthritis Rheum. 2020; 50: 66-70
        • Ungprasert P.
        • Koster M.J.
        • Thongprayoon C.
        • et al.
        Risk of venous thromboembolism among patients with vasculitis: a systematic review and meta-analysis.
        Clin Rheumatol. 2016; 35: 2741-2747
        • Unizony S.
        • Lu N.
        • Tomasson G.
        • et al.
        Temporal Trends of Venous Thromboembolism Risk Before and After Diagnosis of Giant Cell Arteritis.
        Arthritis Rheumatol. 2017; 69: 176-184
        • Michailidou D.
        • Zhang T.
        • Stamatis P.
        • et al.
        Risk of venous and arterial thromboembolism in patients with giant cell arteritis and/or polymyalgia rheumatica: A Veterans Health Administration population-based study in the United States.
        J Intern Med. 2022; 291: 665-675
        • Unizony S.
        • Menendez M.E.
        • Rastalsky N.
        • et al.
        Inpatient complications in patients with giant cell arteritis: decreased mortality and increased risk of thromboembolism, delirium and adrenal insufficiency.
        Rheumatology (Oxford). 2015; 54: 1360-1368
        • Tshifularo N.
        • Arnold M.
        • Moore S.W.
        Thromboembolism and venous thrombosis of the deep veins in surgical children--an increasing challenge?.
        J Pediatr Surg. 2011; 46: 433-436
        • Thomas T.
        • Chandan J.S.
        • Subramanian A.
        • et al.
        Epidemiology, morbidity and mortality in Behçet's disease: a cohort study using The Health Improvement Network (THIN).
        Rheumatology (Oxford). 2020; 59: 2785-2795
        • Toledo-Samaniego N.
        • Galeano-Valle F.
        • Pinilla-Llorente B.
        • et al.
        Clinical features and management of venous thromboembolism in patients with Behçet's syndrome: a single-center case-control study.
        Intern Emerg Med. 2020; 15: 635-644
        • Navarro S.
        • Ricart J.M.
        • Medina P.
        • et al.
        Activated protein C levels in Behçet's disease and risk of venous thrombosis.
        Br J Haematol. 2004; 126: 550-556
        • Abdel Badaee H.
        • Edrees A.
        • Amin S.
        • et al.
        Activated protein C resistance in Behcet's disease.
        Thromb J. 2013; 11: 17
        • Obiorah I.E.
        • Patel B.A.
        • Groarke E.M.
        • et al.
        Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1.
        Blood Adv. 2021; 5: 3203-3215
        • Groarke E.M.
        • Dulau-Florea A.E.
        • Kanthi Y.
        Thrombotic manifestations of VEXAS syndrome.
        Semin Hematol. 2021; 58: 230-238
        • Ungprasert P.
        • Srivali N.
        • Kittanamongkolchai W.
        Risk of venous thromboembolism in patients with Sjögren's syndrome: a systematic review and meta-analysis.
        Clin Exp Rheumatol. 2015; 33: 746-750
        • Aviña-Zubieta J.A.
        • Jansz M.
        • Sayre E.C.
        • et al.
        The Risk of Deep Venous Thrombosis and Pulmonary Embolism in Primary Sjögren Syndrome: A General Population-based Study.
        J Rheumatol. 2017; 44: 1184-1189
        • Mofors J.
        • Holmqvist M.
        • Westermark L.
        • et al.
        Concomitant Ro/SSA and La/SSB antibodies are biomarkers for the risk of venous thromboembolism and cerebral infarction in primary Sjögren's syndrome.
        J Intern Med. 2019; 286: 458-468
        • Li Y.
        • Wang P.
        • Li L.
        • et al.
        Increased risk of venous thromboembolism associated with polymyositis and dermatomyositis: a meta-analysis.
        Ther Clin Risk Manag. 2018; 14: 157-165
        • Carruthers E.C.
        • Choi H.K.
        • Sayre E.C.
        • et al.
        Risk of deep venous thrombosis and pulmonary embolism in individuals with polymyositis and dermatomyositis: a general population-based study.
        Ann Rheum Dis. 2016; 75: 110-116
        • Chung W.S.
        • Lin C.L.
        • Sung F.C.
        • et al.
        Increased risk of venous thromboembolism in patients with dermatomyositis/polymyositis: a nationwide cohort study.
        Thromb Res. 2014; 134: 622-626
        • Parperis K.
        Idiopathic Inflammatory Myopathy and Venous Thromboembolic Events: Comment on the Article by Antovic et al.
        Arthritis Care Res (Hoboken). 2019; 71: 1396
        • Ungprasert P.
        • Srivali N.
        • Kittanamongkolchai W.
        Systemic sclerosis and risk of venous thromboembolism: A systematic review and meta-analysis.
        Mod Rheumatol. 2015; 25: 893-897
        • Butt S.A.
        • Jeppesen J.L.
        • Torp-Pedersen C.
        • et al.
        Cardiovascular Manifestations of Systemic Sclerosis: A Danish Nationwide Cohort Study.
        J Am Heart Assoc. 2019; 8: e013405
        • Schoenfeld S.R.
        • Choi H.K.
        • Sayre E.C.
        • et al.
        Risk of Pulmonary Embolism and Deep Venous Thrombosis in Systemic Sclerosis: A General Population-Based Study.
        Arthritis Care Res (Hoboken). 2016; 68: 246-253
        • Johnson S.R.
        • Hakami N.
        • Ahmad Z.
        • et al.
        Venous Thromboembolism in Systemic Sclerosis: Prevalence, Risk Factors, and Effect on Survival.
        J Rheumatol. 2018; 45: 942-946
        • Furtado S.
        • Dunogué B.
        • Jourdi G.
        • et al.
        High D-dimer plasma concentration in systemic sclerosis patients: Prevalence and association with vascular complications.
        J Scleroderma Relat Disord. 2021; 6: 178-186
        • Johannesdottir S.A.
        • Schmidt M.
        • Horváth-Puhó E.
        • et al.
        Autoimmune skin and connective tissue diseases and risk of venous thromboembolism: a population-based case-control study.
        J Thromb Haemost. 2012; 10: 815-821
        • Horton D.B.
        • Xie F.
        • Chen L.
        • et al.
        Oral Glucocorticoids and Incident Treatment of Diabetes Mellitus, Hypertension, and Venous Thromboembolism in Children.
        Am J Epidemiol. 2021; 190: 403-412
        • Ungprasert P.
        • Srivali N.
        • Wijarnpreecha K.
        • et al.
        Sarcoidosis and risk of venous thromboembolism: A systematic review and meta-analysis.
        Sarcoidosis Vasc Diffuse Lung Dis. 2015; 32: 182-187
        • Ungprasert P.
        • Crowson C.S.
        • Matteson E.L.
        Epidemiology and clinical characteristics of sarcoidosis: an update from a population-based cohort study from Olmsted County, Minnesota.
        Reumatismo. 2017; 69: 16-22
        • Ungprasert P.
        • Crowson C.S.
        • Matteson E.L.
        Association of Sarcoidosis With Increased Risk of VTE: A Population-Based Study, 1976 to 2013.
        Chest. 2017; 151: 425-430
        • Parrish S.C.
        • Lin T.K.
        • Sicignano N.M.
        • et al.
        Sarcoidosis in the United States Military Health System.
        Sarcoidosis Vasc Diffuse Lung Dis. 2018; 35: 261-267
        • Kolluri N.
        • Elwazir M.Y.
        • Rosenbaum A.N.
        • et al.
        Effect of Corticosteroid Therapy in Patients With Cardiac Sarcoidosis on Frequency of Venous Thromboembolism.
        Am J Cardiol. 2021; 149: 112-118
        • Cox P.
        • Gupta S.
        • Zhao S.S.
        • et al.
        The incidence and prevalence of cardiovascular diseases in gout: a systematic review and meta-analysis.
        Rheumatol Int. 2021; 41: 1209-1219
        • Li L.
        • McCormick N.
        • Sayre E.C.
        • et al.
        Trends of venous thromboembolism risk before and after diagnosis of gout: a general population-based study.
        Rheumatology (Oxford). 2020; 59: 1099-1107
        • Sultan A.A.
        • Muller S.
        • Whittle R.
        • et al.
        Venous thromboembolism in patients with gout and the impact of hospital admission, disease duration and urate-lowering therapy.
        CMAJ. 2019; 191: E597-E603
        • Kearon C.
        • Akl E.A.
        • Ornelas J.
        • et al.
        Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report.
        Chest. 2016; 149: 315-352
        • Tektonidou M.G.
        • Andreoli L.
        • Limper M.
        • et al.
        EULAR recommendations for the management of antiphospholipid syndrome in adults.
        Ann Rheum Dis. 2019; 78: 1296-1304
        • Cerdà P.
        • Becattini C.
        • Iriarte A.
        • et al.
        Direct oral anticoagulants versus vitamin K antagonists in antiphospholipid syndrome: A meta-analysis.
        Eur J Intern Med. 2020; 79: 43-50
        • Dufrost V.
        • Wahl D.
        • Zuily S.
        Direct oral anticoagulants in antiphospholipid syndrome: Meta-analysis of randomized controlled trials.
        Autoimmun Rev. 2021; 20: 102711
        • Tenti S.
        • Guidelli G.M.
        • Bellisai F.
        • et al.
        Long-term treatment of antiphospholipid syndrome with intravenous immunoglobulin in addition to conventional therapy.
        Clin Exp Rheumatol. 2013; 31: 877-882
        • He M.
        • Pawar A.
        • Desai R.J.
        • et al.
        Risk of venous thromboembolism associated with methotrexate versus hydroxychloroquine for rheumatoid arthritis: A propensity score-matched cohort study.
        Semin Arthritis Rheum. 2021; 51: 1242-1250
        • Jorge A.
        • Lu N.
        • Choi H.
        • et al.
        Hydroxychloroquine Use and Cardiovascular Events Among Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis.
        Arthritis Care Res (Hoboken). 2021; (In press)https://doi.org/10.1002/acr.24850
        • Chen C.P.
        • Kung P.T.
        • Chou W.Y.
        • et al.
        Effect of introducing biologics to patients with rheumatoid arthritis on the risk of venous thromboembolism: a nationwide cohort study.
        Sci Rep. 2021; 11: 17009
        • Korswagen L.A.
        • Bartelds G.M.
        • Krieckaert C.L.
        • et al.
        Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study.
        Arthritis Rheum. 2011; 63: 877-883
        • Baldini C.
        • Moriconi F.R.
        • Galimberti S.
        • et al.
        The JAK-STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms.
        Eur Heart J. 2021; 42: 4389-4400
        • Ytterberg S.R.
        • Bhatt D.L.
        • Mikuls T.R.
        • et al.
        Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
        N Engl J Med. 2022; 386: 316-326
        • Singh J.A.
        Risks and Benefits of Janus Kinase Inhibitors in Rheumatoid Arthritis - Past, Present, and Future.
        N Engl J Med. 2022; 386: 387-389
        • Mease P.
        • Charles-Schoeman C.
        • Cohen S.
        • et al.
        Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
        Ann Rheum Dis. 2020; 79: 1400-1413
        • Desai R.J.
        • Pawar A.
        • Khosrow-Khavar F.
        • et al.
        Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study.
        Rheumatology (Oxford). 2021; 61: 121-130
        • Fleischmann R.
        • Mysler E.
        • Bessette L.
        • et al.
        Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study.
        RMD Open. 2022; 8: e002012
        • Yates M.
        • Mootoo A.
        • Adas M.
        • et al.
        Venous Thromboembolism Risk With JAK Inhibitors: A Meta-Analysis.
        Arthritis Rheumatol. 2021; 73: 779-788
        • Buch M.H.
        • Charles-Schoeman C.
        • Curtis J.
        • et al.
        POS0237 major adverse cardiovascular events, malignancies and venous thromboembolism by baseline cardiovascular risk: a post hoc analysis of oral surveillance.
        Ann Rheum Dis. 2022; 81: 356
        • Charles-Schoeman C.
        • Fleischmann R.M.
        • Mysler E.
        • et al.
        POS0239 risk of venous thromboembolic events in patients with rheumatoid arthritis aged ≥50 years with ≥1 cardiovascular risk factor: results from a phase 3b/4 randomised study of tofacitinib vs tumour necrosis factor inhibitors.
        Ann Rheum Dis. 2022; 81: 358
        • Seyahi E.
        • Yurdakul S.
        Behçet's Syndrome and Thrombosis.
        Mediterr J Hematol Infect Dis. 2011; 3: e2011026
        • Goodman S.M.
        • Bass A.R.
        Perioperative medical management for patients with RA, SPA, and SLE undergoing total hip and total knee replacement: a narrative review.
        BMC Rheumatol. 2018; 2: 2
        • Gualtierotti R.
        • Parisi M.
        • Ingegnoli F.
        Perioperative Management of Patients with Inflammatory Rheumatic Diseases Undergoing Major Orthopaedic Surgery: A Practical Overview.
        Adv Ther. 2018; 35: 439-456
        • Martinez C.
        • Wallenhorst C.
        • Teal S.
        • et al.
        Incidence and risk factors of chronic thromboembolic pulmonary hypertension following venous thromboembolism, a population-based cohort study in England.
        Pulm Circ. 2018; 8 (2045894018791358)
        • Almaaitah S.
        • Highland K.B.
        • Tonelli A.R.
        Management of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis.
        Integr Blood Press Control. 2020; 13: 15-29
        • Chang S.H.
        • Park J.K.
        • Lee Y.J.
        • et al.
        Comparison of cancer incidence among patients with rheumatic disease: a retrospective cohort study.
        Arthritis Res Ther. 2014; 16: 428
        • Kim S.C.
        • Schneeweiss S.
        • Liu J.
        • et al.
        Risk of venous thromboembolism in patients with rheumatoid arthritis.
        Arthritis Care Res (Hoboken). 2013; 65: 1600-1607
        • Enga K.F.
        • Braekkan S.K.
        • Hansen-Krone I.J.
        • et al.
        Cigarette smoking and the risk of venous thromboembolism: the Tromsø Study.
        J Thromb Haemost. 2012; 10: 2068-2074
        • Bernier M.O.
        • Mikaeloff Y.
        • Hudson M.
        • et al.
        Combined oral contraceptive use and the risk of systemic lupus erythematosus.
        Arthritis Rheum. 2009; 61: 476-481